title: The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer.
abstract: Four hundred and seventeen patients with newly diagnosed superficial bladder tumours (Ta or T1) were treated with complete transurethral resection and then randomised between three groups. Group 1 had an instillation of 30 mg thiotepa at the time of primary treatment. Group 2 had instillations of thiotepa at 3-monthly intervals for a year. Group 3 was given no instillation. Regular check cystoscopies revealed no significant difference in the rate at which tumours recurred in the three groups (p = 0.4 and P = 0.7 for control vs thiotepa given once and five times respectively). It was concluded that neither thiotepa regimen produced sufficient improvement to justify its use in this group of patients.
mesh_terms: D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003558:Cystoscopy; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011897:Random Allocation; D013852:Thiotepa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D013852:Thiotepa